1. Nelson L. Epidemiology of ALS. Clin Neurosci 1996; 3(6): 327-331.

      2. Majoor-Krakaauer D, Willems P, Hofman A. Genetic epidemiology of amyotrophic lateral sclerosis. Clin Genet 2003; 63(2): 83-101.

      3. Liu D, Wen J, Liu J, Li L. The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospho­lipids. FASEB J 1999; 13(15): 2318-2328.

      4. Noor R, Mittal S, Iqbal J. Superoxide dismutase – applications and relevance to human diseases. Med Sci Monit 2002; 8(9): 210-215.

      5. Andersen PM. Genetics of sporadic ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2(Suppl 1): S37-S41.

      6. Andersen PM, Sims KB, Xin WW, Kiely R, O'Neill G, Ravits J, Pioro E, Harati Y, Brower RD, Levine JS, Heinicke HU, Seltzer W, Boss M, Brown RH Jr. Sixteen novel muta­tions in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4(2): 62-73.

      7. Skvortsova V, Limborskaia S, Slominskii P, Levitskii G, Levitskaia N, Shadrina MI Kondrat’eva E, Brusov O, Lysko A, Karakhan V, Alekhin A, Serdiuk A. Peculiarities of sporadic motor neuron disease associated with D90A and G12R mutations in Russian population. Zh Nevrol Psikhiatr Im S S Korsakova 2003; 103(11): 46-52.

      8. Bertz R, Granneman G. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic inter­actions. Clin Pharmacokinet 1997; 32(3): 210-258.

      9. Forsyth J, Grünewald R, Rostami-Hodjegan A, Lennard M, Sagar H, Tucker G. Parkinson’s disease and CYP1A2 activity. Br J Clin Pharmacol 2000; 50(4): 303-309.

      10. Siddons M, Pickering-Brown S, Mann D, Owen F, Cooper P. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis. Neurosci Lett 1996; 208(1): 65-68.

      11. Borroni B, Archetti S, Agosti C, Akkawi N, Brambilla C, Caimi L, Caltagirone C, Di Luca M, Padovani A. Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: from risk factors to disease modulators. Neurobiol Aging 2004; 25(6): 747-751.

      12. Fritsche E, Pittman G, Bell D. Localization, sequence analysis, and ethnic distribution of a 96-br insertion in the promoter of the human CYP2E1 gene. Mutat Res Genom 2000; 432(1-2): 1-5.

      13. Ingelman-Sundberg M, Oscarson M, McLellan R. Polymorphic human cytochrome P450 enzymes: an opportu­nity for individualized drug treatment. Trends Pharmacol Sci 1999; 20(8): 342-349.

      14. Santt O, Baranova H, Albuisson E, Bignon Y, Lucotte G. Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson’s disease. Eur J Neurol 2004; 11(4): 247-251.

      15. Cacabelos R. The application of functional genomics to Alzheimer’s disease. Pharmacogenomics 2003; 4(5): 597-621.

      16. Sachse C, Brockmoller J, Bauer S, Roots I. Cyto­chrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60(2): 284-295.

      17. James C, Daniels J, Wiles C, Owen M. Debrisoquine hydroxylase gene polymorphism in motor neuron disease. Neurodegeneration 1994; 3(1): 149-152.

      18. Pickett C, Lu A. Glutathione S-transferases: gene structure, regulation, and biological function. Annu Rev Bio­chem 1989; 58: 743-764.

      19. Suzuki T, Coggan M, Shaw D, Board P. Electropho­retic and immunological analysis of human glutathione S-transferase isozymes. Ann Hum Genet 1987; 51(Pt 2): 95-106.

      20. Rebbeck T. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997; 6(9): 733-743.

      21. Harries L, Stubbins M, Forman D, Howard G, Wolf C. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997; 18(4): 641-644.

      22. Hatagima A. Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility. Cad Saude Publica 2002; 18(2): 357-377.

      23. Stroombergen M, Waring R. Determination of gluta­thione S-transferase mu and theta polymorphisms in neuro­logical disease. Hum Exp Toxicol 1999; 18(3): 141-145.

      24. Spielberg S. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996; 24(5): 509-519.

      25. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57(3): 581-592.

      26. Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, Gelatti U, Spaliviero M, Placidi D, Carta A, Scotto di Carlo A, Porru S. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environ­mental exposures and bladder cancer risk in a high-risk popu­lation. Int J Cancer 2004; 110(4): 598-604.

      27. Bandmann O, Vaughan J, Holmans P, Marsden C, Wood N. Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson’s disease. Mov Disord 2000; 15(1): 30-35.

      28. Steventon G, Heafield M, Waring R, Williams A. Xenobiotic metabolism in Parkinson's disease. Neurology 1989; 39(7): 883-887.

      29. Brooks BR, Miller RG, Swash M, Munsat TL, the World Federation of Neurology Research Group on Motor Neuron Diseases; El Escorial. Revised criteria for the diag­nosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1(1): 293-299.

      30. Norris F, Shepherd R, Denys E, U, Mukai E, Elias L, Holden D, Norris H. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993; 118(1): 48-55.

      31. Norris F, Callachini P, Fallat R, Panchari S, Jewett B. Administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974; 24(8): 721-728.

      32. Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988; 16(3): 1215.

      33. Brown M, Edwards S, Hoyle E, Campbell S, Laval S, Daly A, Pile K, Calin A, Ebringer A, Weeks D, Wordsworth B. Polymorphisms of the CYP2D6 gene increase susceptibil­ity to ankylosing spondylitis. Hum Mol Genet 2000; 9(11): 1563-1566.

      34. Abdel-Rahman S, el-Zein R, Anwar W, Au W. A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett 1996; 107(2): 229-233.

      35. Watson M, Stewart R, Smith G, Massey T, Bell D. Human glutathione S-transferase P1 polymorphisms: relation­ship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19(2): 275-280.

      36. Baranova H, Canis M, Ivaschenko T, Albuisson E, Bothorishvilli R, Baranov V, Malet P, Bruhat MA. Possible involvement of arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 genes in the development of endo­metriosis. Mol Hum Reprod 1999; 5(7): 636-641.

      37. Raymond ML, Rousset F. An exact test for popula­tion differentiation. Evolution 1995; 49(6): 1280-1283.

      38. Zherebtsova A, Shadrina M, Levitsky G, Levintskaia N, Alekhin A, Slominskii P, Skvortsova V, Limborskaia S. Analysis of the glutathione S-transferase P1 gene Ile105Val polymorphism in the patients with sporadic motor neuron disease from Russia. Genetika 2004; 40(6): 850-852.

      39. Harris MJ, Coggan M, Langton L, Wilson S, Board P. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics 1998; 8(1): 27-31.

      40. Saarikoski S, Voho A, Reinikainen M, Anttila S, Karjalainen A, Malaveille C, VainioH, Husgafvel-Pursiainen K, Hirvonen A. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer 1998, 77(4): 516-521.

      41. Bachus R, Neubert K, Roots I, Prudlo J, Brockmoller J, Ludolph A. Polymorphisms of toxifying and detoxifying hepatic enzymes in amyotrophic lateral sclerosis. J Neurol Neurosurg Psych 2003; 74(8): 1161.

      42. Zima T, Fialova L, Mestek O, Janebova M, Crkovska J, Malbohan I, Stipek S, Mikulikova L, Popov P. Oxidative stress, metabolism of ethanol and alcohol-related diseases. J Biomed Sci 2001; 8(1): 59-70.

43. Montoliu C, Sancho-Tello M, Azorin I, Burgal M, Valles S, Renau-Piqueras J, Guerri C. Ethanol increases cyto­chrome P4502E1 and induces oxidative stress in astrocytes. J Neurochem 1995; 65(6): 2561-2570.

44. Giess R, Holtmann B, Braga M, Grimm T, Muller-Myhsok B, Toyka K, Sendtner M.; Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am J Hum Genet 2002; 70(5): 1277-1286.

45. Fryer AA, Zhao L, Alldersea J, Pearson W, Strange R. Use of site-directed mutagenesis of allele-specific PCR primers to identify the GSTM1 A, GSTM1 B, GSTM1 A,B and GSTM1 null polymorphisms at the glutathione S-trans­ferase, GSTM1 locus. Biochem J 1993; 295(Pt 1): 313-315.